Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612570 | PMC |
| http://dx.doi.org/10.1002/cpt.1409 | DOI Listing |
Publication Analysis
Top Keywords
cytochrome p450
8
p450 cyp2d6
8
cyp2d6 genotype
8
clinical pharmacogenetics
4
pharmacogenetics implementation
4
implementation consortium
4
consortium guideline
4
guideline cytochrome
4
atomoxetine
4
genotype atomoxetine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!